Zanubrutinib Shows 5-Year PFS Benefit in R/R CLL/SLL | Targeted Oncology

Zanubrutinib (Brukinsa) yielded durable efficacy and sustained progression-free survival (PFS) benefit in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), according to data from the…